• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Akanda Corp.

    5/13/24 5:22:58 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AKAN alert in real time by email
    S-8 1 ea0205709-s8_akanda.htm REGISTRATION STATEMENT

     

    As filed with the Securities and Exchange Commission on May 13, 2024

    Registration No. 333-       

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    AKANDA CORP.

    (Exact name of registrant as specified in its charter)

     

    Ontario, Canada   Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    Akanda Corp.    
    1a, 1b Learoyd Road    
    New Romney TN28 8XU, United Kingdom   Not Applicable
    (Address of Principal Executive Offices)   (Zip Code)

     

    AKANDA CORP. 2024 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    C T Corporation System

    1015 15th Street N.W., Suite 1000

    Washington, DC 20005

    (Name and address of agent for service)

     

    1 (866) 925-9916

    (Telephone number, including area code, of agent for service)

     

    with a copy to:

     

    Mark C. Lee

    Rimon, P.C.

    423 Washington Street, Suite 600

    San Francisco, CA 94111

    (916) 603-3444

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by Akanda Corp., a corporation organized under the laws of the Province of Ontario, Canada (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) are incorporated by reference herein:

     

    (a)The Registrant’s annual report on Form 20-F filed with the Commission on May 1, 2024; and

     

    (b)The description of the Registrant’s common shares contained in Exhibit 2.1 to its annual report on Form 20-F filed with the Commission on May 1, 2024, including any amendments or reports filed for the purpose of updating such description.

     

    All documents filed and to be filed by the Registrant with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), subsequent to the effectiveness of this Registration Statement on Form S-8 (this “Registration Statement”) and, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective date of filing of such documents. The Registrant’s Exchange Act file number with the Commission is 001-41324. In addition, any Report on Form 6-K of the Registrant hereafter furnishes to the Commission pursuant to the Exchange Act shall be incorporated by reference into this Registration Statement if and to the extent provided in such document.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    In accordance with the Business Corporations Act (Ontario) and pursuant to the bylaws of the Registrant (the “Bylaws”), subject to certain conditions, the Registrant shall, to the maximum extent permitted by law, indemnify a director or officer, a former director or officer, or another individual who acts or acted at the Registrant’s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including any amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the Registrant or other entity. The Registrant shall advance monies to a director, officer or other individual for costs, charges and expenses reasonably incurred in connection with such a proceeding; provided that such individual shall repay the moneys if the individual does not fulfill the conditions described below or is not successful on the merits in their defense of the action or proceeding. Indemnification is prohibited unless the individual:

     

    ●acted honestly and in good faith with a view to the Registrant’s best interests;

     

    ●in the case of a criminal or administration action or proceeding enforced by a monetary penalty, had reasonable grounds to believe the conduct was lawful; and

     

    ●was not judged by a court or other competent authority to have committed any fault or omitted to do anything that the individual ought to have done

      

    The Registrant also has entered into indemnification agreements with each of the Registrant’s executive officers and directors. The indemnification agreements provide the indemnitees with contractual rights to indemnification, and expense advancement and reimbursement, to the fullest extent permitted under Ontario law.

     

    Item 7. Exemption From Registration Claimed.

     

    Not applicable.

     

    II-1

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement and are numbered in accordance with Item 601 of Regulation S-K:

     

    5.1  Opinion of Gowling WLG (Canada) LLP
    23.1  Consent of Green Growth CPAs, independent registered public accounting firm
    23.2  Consent of Gowling WLG (Canada) LLP (included in Exhibit 5.1 to this Registration Statement)
    24.1  Power of Attorney (included in signature page to this Registration Statement)
    107  Filing Fee Table

     

    Item 9. Undertakings

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

     

    (iii)to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (2) that, for the purpose of determining any liability under the Securities Act of 1933, as amended (the “Securities Act”), each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act ) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Fort Lauderdale, the United States, on May 13, 2024.

     

      AKANDA CORP.
         
      By:  /s/ Katie Field Katie Field
        Interim Chief Executive Director and Director

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Katie Field as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or her might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Katie Field   Interim Chief Executive Officer and Director   May 13, 2024
    Katie Field   (Principal Executive Officer)    
             
    /s/ Gurcharn Deol   Chief Financial Officer   May 13, 2024
    Gurcharn Deol   (Principal Financial and Accounting Officer)    
             
    /s/ Christopher Cooper   Director   May 13, 2024
    Christopher Cooper        
             
    /s/ Jatinder Dhaliwal   Director   May 13, 2024
    Jatinder Dhaliwal        
             
    /s/ David Jenkins   Director   May 13, 2024
    David Jenkins        

     

    II-3

     

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKAN
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by Akanda Corp.

    F-1/A - AKANDA CORP. (0001888014) (Filer)

    1/28/26 10:54:22 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form F-1 filed by Akanda Corp.

    F-1 - AKANDA CORP. (0001888014) (Filer)

    1/26/26 5:25:59 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    1/23/26 5:25:16 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Hrt Financial Lp claimed ownership of 15,684 units of Class A Shares (SEC Form 3)

    3 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 1:36:34 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AKAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Akanda Corp. Announces Reverse Stock Split

    Toronto, Ontario--(Newsfile Corp. - January 8, 2026) - Akanda Corp. (NASDAQ:AKAN) (the "Company" or "Akanda"), today announced that it expects to implement a 1-for-5 reverse stock split of the Company's common shares effective January 12, 2026. The reverse stock split was previously approved by the Company's shareholders on November 28, 2025 and Board of Directors on December 23, 2025 and will begin trading on an adjusted basis giving effect to the reverse stock split at the opening of market on January 12, 2026 under the existing ticker symbol "AKAN". The new CUSIP number of the Company's common shares will be 00971M601 and the new ISIN code will be CA00971M6018.In accordance with the propo

    1/8/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Akanda Corp. Welcomes Momentum Towards Cannabis Reform in the United States

    Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company") applauds the recent reports that US President Donald Trump and his administration are considering changes and the reclassification of federal cannabis policy in the USA, including potential rescheduling of cannabis from Schedule I to Schedule III. Schedule III drugs are considered to have a medical value and a lower abuse potential as defined by the Drug Enforcement Administration."Cannabis policies are long overdue for modernization," said Interim CEO Katie Field. "The US Administration is taking steps to treat cannabis through a science-led, public-health framework which has the

    12/18/25 7:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    RETRANSMISSION: Akanda Researching Security Requirements for Full Cultivation License

    Toronto, Ontario--(Newsfile Corp. - November 14, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company") is researching the security requirements and next steps for a full cultivation license through its cannabis operating subsidiary. Recently, the Company extended its option on its British Columbia asset for an additional two years. While the Company currently operates under its hemp cultivation license, Akanda plans to advance toward a full cultivation license for a range of potential THC products and, in parallel, intends to design and commence the build-out of Health Canada–compliant security measures at the site. This planned security program—anticipated to require enhanced perim

    11/14/25 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Leadership Updates

    Live Leadership Updates

    View All

    Halo Collective Announces Change of Auditors and Failure to File Cease Trade Order

    Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Halo Collective Inc. (NEO: HALO) (OTCQB:HCANF) (FSE: A9K0) ("Halo" or the "Company") announces today that it has changed its auditor (the "Change of Auditor") from Macias Gini & O'Connell LLP (the "Former Auditor") to GreenGrowth CPAs (the "Successor Auditor"). The Former Auditor resigned effective June 19, 2023, and the Company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.There was no modified opinion, or other opinion, issued by the Former Auditor in connection with its audit of the Co

    6/22/23 1:06:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Canmart Ends CEO Service Agreement; Akanda Approves Appointment of Director

    International medical cannabis platform company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk's Service Agreement dated June 2, 2021 (the "Service Agreement") to an immediate end with effect from February 13th, 2023. As disclosed on February 7th, 2023, the Company disclosed Mr. Virk's attempt to end the Service Agreement without providing the requisite period of notice required under the Service Agreement, his interpretation of the Service Agreement, and allegations of Breach of Contract. On February 13th, 2023, the Company informed Mr. Virk that it had reached the conclusion that it has a right to bring the Service

    2/16/23 5:05:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    /R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/

    TORONTO, Aug. 12, 2022 /PRNewswire/ -  Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced the appointment of Katie Field, Chief Executive Officer of Halo, to Chairman of the board of directors of the Company (the "Board"), effective immediately. Current Chairman Ryan Kunkel has resigned from the Board to focus on other professional endeavors. To the knowledge of the Company, Ms. Field is the second woman to serve as Chairman and CEO of a publicly traded cannabis company, the first being Kim Rivers of Trulieve (CSE:TRUL). Ca

    8/12/22 8:00:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Financials

    Live finance-specific insights

    View All

    Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon

    TORONTO, Sept. 22, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced, further to its press release dated August 27, 2021, that it has completed the acquisition of all of the substantial assets of three operating entities doing business as Pistil Point in Oregon which collectively hold multiple cannabis licenses. With this transaction, Halo now has full ownership of a range of indoor and outdoor cultivation, manufacturing, and distributions assets, along with an expanded library of genetics that is expected to allow the Company to continue to execute its vertically integrated strategy in Oregon with enhanced compet

    9/22/22 5:00:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Halo Collective Announces Westwood Dispensary Completion, Local Inspections Passed, and Planned Opening for Second Budega™ in California

    TORONTO, April 12, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced that its Budega Westwood Dispensary passed its Los Angeles inspection and is expected to open within 30 days. The Budega Westwood location is perfectly located nestled in between Westwood to the west and Beverly Hills to the east, right off of one of LA's most traveled and famous thoroughfares for locals and visitors, the Santa Monica Boulevard (10461 Santa Monica Blvd) and within two miles of the University of Los Angeles California campus. The facility is leased and near complete with renovations of its approximately 1,500 square foot prime retail

    4/12/22 4:40:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Akanda Corp. (Amendment)

    SC 13D/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 6:01:03 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Akanda Corp.

    SC 13D - AKANDA CORP. (0001888014) (Subject)

    2/20/24 5:17:13 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Akanda Corp. (Amendment)

    SC 13G/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 12:55:32 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care